Top Markets
Coin of the day
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rankning i aktier #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Aktiekurs
$451.59
Marknadsvärde
$114.70B
Förändring (1 dag)
-2.36%
Förändring (1 år)
-11.89%
Land
US
Handel Vertex Pharmaceuticals Incorporated (VRTX)

Kategori

P/S-tal för Vertex Pharmaceuticals Incorporated (VRTX)
P/S-tal per March 2026 TTM: 9.90
Enligt Vertex Pharmaceuticals Incorporated senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 9.90. I slutet av 2023 hade företaget ett P/S-tal på 10.62.
Historik för P/S-tal för Vertex Pharmaceuticals Incorporated från 2000 till 2026
P/S-tal vid årets slut
År P/S-tal Ändra
2026 (TTM) 9.90 5.24%
2024 9.41 -11.43%
2023 10.62 28.30%
2022 8.28 10.84%
2021 7.47 -24.50%
2020 9.90 -26.71%
2019 13.50 -2.34%
2018 13.83 -7.73%
2017 14.99 42.14%
2016 10.54 -64.09%
2015 29.36 -38.95%
2014 48.08 248.85%
2013 13.78 137.01%
2012 5.82 20.56%
2011 4.82 -90.15%
2010 48.96 -32.70%
2009 72.75 199.01%
2008 24.33 61.60%
2007 15.06 -23.11%
2006 19.58 27.59%
2005 15.35 89.82%
2004 8.09 -29.86%
2003 11.53 54.66%
2002 7.45 -31.82%
2001 10.93 -82.35%
2000 61.94 0.00%
P/S-tal för liknande företag eller konkurrenter
Företag P/S-tal Skillnad i P/S-tal Land
3.55 -64.14%
DK
5.40 -45.44%
US
6.14 -38.02%
BE
3.04 -69.26%
AU
12.90 30.24%
NL